Similar articles

• Viral resistance and the selection of antiretroviral combinations.

  Larder BA. Larder BA. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S28-33. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 8595505 Review.
• Clinical implications of resistance to antiretroviral drugs.

  Vella S. Vella S. AIDS Clin Care. 1997 Jun;9(6):45-7, 49, 52. AIDS Clin Care. 1997. PMID: 11364354
• [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].

  Salomon HE, Pampuro SE, Gu Z, Montaner JS, Libonatti O, Wainberg MA. Salomon HE, et al. Rev Argent Microbiol. 1995 Oct-Dec;27(4):214-29. Rev Argent Microbiol. 1995. PMID: 8850135 Review. Spanish. No abstract available.
• Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

  Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B. Back NK, et al. EMBO J. 1996 Aug 1;15(15):4040-9. EMBO J. 1996. PMID: 8670908 Free PMC article.
• Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.

  Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B. Jeeninga RE, et al. Virology. 2001 May 10;283(2):294-305. doi: 10.1006/viro.2001.0888. Virology. 2001. PMID: 11336554